$1.12
+0.07
(+6.67%)▲
Live
4.55%
Downside
Day's Volatility :9.41%
Upside
5.08%
9.82%
Downside
52 Weeks Volatility :99.75%
Upside
99.72%
Period | Aditxt Inc | Index (Russel 2000) |
---|---|---|
3 Months | -98.12% | 0.0% |
6 Months | -98.82% | 0.0% |
1 Year | -99.68% | 0.0% |
3 Years | -100.0% | -23.0% |
Market Capitalization | 4.6M |
Book Value | $131.74 |
Earnings Per Share (EPS) | -1375.2 |
Wall Street Target Price | 61.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -13497.11% |
Return On Assets TTM | -117.61% |
Return On Equity TTM | -3493.63% |
Revenue TTM | 329.7K |
Revenue Per Share TTM | 12.11 |
Quarterly Revenue Growth YOY | -80.0% |
Gross Profit TTM | 166.9K |
EBITDA | -33.1M |
Diluted Eps TTM | -1375.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 5346.43%
Sell
Neutral
Buy
Aditxt Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Aditxt Inc | -90.24% | -98.82% | -99.68% | -100.0% | -100.0% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Aditxt Inc | NA | NA | NA | 0.0 | -34.94 | -1.18 | NA | 131.74 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Aditxt Inc | Sell | $4.6M | -100.0% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Aditxt Inc
Revenue is down for the last 5 quarters, 220.97K → 44.27K (in $), with an average decrease of 31.2% per quarter
Netprofit is up for the last 2 quarters, -14.72M → -7.54M (in $), with an average increase of 95.1% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 182.6%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 144.8%
Geode Capital Management, LLC
Tower Research Capital LLC
Group One Trading, LP
IFP Advisors, LLC
a biotech company with a mission to accelerate humanity’s transition to the "age of immunity", we are the business busily decoding the human immune system.
Organization | Aditxt Inc |
Employees | 47 |
CEO | Mr. Amro A. Albanna |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.12
+6.67%
Invesco Bulletshares 2025 Hi
$1.12
+6.67%
Schwab International Dividend Equity Etf
$1.12
+6.67%
Blockchain Coinvestors Acquisition Corp.
$1.12
+6.67%
Allgiant Travel Company
$1.12
+6.67%
Rogers Corp
$1.12
+6.67%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.12
+6.67%
Iheartmedia
$1.12
+6.67%
Lightpath Technologies Inc
$1.12
+6.67%